PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)
Abstract
Authors
A Shim D Trone M Reynolds D Odom B Sherif S Stopatschinskaja